期刊文献+

帕洛诺司琼联合地塞米松预防术后恶心呕吐的临床观察 被引量:6

CLINICAL OBSERVATION OF THE EFFECT OF SINGLE PALONOSETRON OR COMBINED WITH DEXAMETHASONE TO PREVENT POST-OPERATIVE NAUSEA AND VOMITING
下载PDF
导出
摘要 目的观察单独使用帕洛诺司琼及联合地塞米松预防妇科手术术后恶心呕吐的有效性及安全性。方法选择在气管内全麻的妇科患者40例,ASAⅠ~Ⅱ级,均采用静脉镇痛,随机分为两组:帕洛诺司琼0.075 mg+生理盐水1 ml组(A组,n=20),帕洛诺司琼0.075 mg+地塞米松5 mg组(B组,n=20)。开始麻醉诱导前予以帕洛诺司琼和生理盐水或地塞米松,观察术后0~24、~72 h的治疗失败率与0~6、~72及0~72 h的完全缓解率(CR)、恶心程度及治疗失败时间(TTF)。结果①术后两组的完全缓解率无显著性差异;②两组恶心程度评分无显著性差异。③B组0~24 h的治疗失败率为15%,明显减少(p=0.041)。结论妇科手术前静脉注射单剂量的帕洛诺司琼0.15 mg联合地塞米松5 mg不能改善恶心呕吐的完全缓解率,但能降低0~24 h的治疗失败率。 Objective To observe the efficacy and safety of a single IV dose of palonosetron or combined with dexamethasone on the effectiveness and security of preventing postoperative nausea and vomiting (PONV) for gynecological surgery. Methods Forty patients (ASA I - II ) undergoing gynecological surgery with general anesthesia, scheduled for intravenous analgesia were divided into two groups randomly: Group A (palonosetron 0. 075mg + saline 1 ml, n = 20) and Group B(palonosetron 0. 15 mg + dexamethasone 5 rag, n = 20). A single dose of palonosetron (0.075 rag) and saline or dexamethasone was administered immediately before induction of anesthesia. Complete response (CR: no emetic episodes and no rescue medication) ,nausea severity and TIT( time to treatment fail- ure) were observed during the 0 to 24 h, 24 to 72 h,0 to6h ,6 to 72 h and 0 to 72 h postoperative time intervals. Resuits (1) CR rates were similar. (2)Nausea severity were similar. (3)The proportion of treatment failure is significantly decreased for the 0 to 24 h interval in Group B (p = 0. 041 ). Conclusion A single 0. 15mg IV dose of palonosetron combined with dexamethasone 5 mg before gynecological surgery significantly decreased the proportion of treatment failure for 0 - 24 h without increasing the CR.
出处 《现代医院》 2011年第11期20-22,共3页 Modern Hospitals
关键词 帕洛诺司琼 地塞米松 术后恶心呕吐 Palonosetron, Dexamethasone, Postoperative nausea and vomiting (PONV)
  • 相关文献

参考文献13

  • 1APFEL C C, LAARA E, KOIVURANTA M, et al. A simpli? ed risk score for predicting postoperative nausea and vomiting: con- clusions from cross - validations between two centers [ J ]. Anes~ thesiology, 1999,91 (3) :693 - 700.
  • 2MYLES P S, WILLIAMS D L, HENDRATA M, et al. Patient sat- isfaction after anaesthesia and surgery: results of a prospective sur- vey of 10,811 patients[ J]. Br J Anaesth, 2000,84( 1 ) :6 - 10.
  • 3GAN T J. Risk factors for postoperative nausea and vomiting[ J]. Anesth Analg, 2006,102(6) : 1884 - 1898.
  • 4VAN DEN BOSCH J E, BONSEL G J, MOONS K G,et 81. Effect of postoperative experiences on willingness to pay to avoid postop- erative pain, nausea, and vomiting [ J ]. Anesthesiology,2006,104 ( 5 ) : 1033 - 1039.
  • 5SINCLAIR D R, CHUNG F, MEZEI G. Can postoperative nausea and vomiting be predicted[J]. Anesthesiology, 2003,98 ( 1 ) :46 -52.
  • 6ROBERTS G W, BEKKER T B, CARLSEN H H, et al. Postop- erative nausea and vomiting are strongly influenced by postopera- tive opioid use in a dose - related manner [ J ]. A~esth Analg, 2005,101 (5) : 1343 - 1348.
  • 7MAHARAJ C H, KALLAM S R, MALIK A, et al. Preoperative intravenous fluid therapy decreases postoperative nausea and pain in high risk patients [ J]. Anesth Analg, 2005,100 ( 3 ) : 675 - 682.
  • 8STOLTZ R, CYONG J C, SHAH A, et 81. Pharmacokinetic and safety evaluation of palonosetron, a 5 - hydroxytryptamine - 3 re- ceptor antagonist, in U.S. and Japanese healthy subjects[J]. J Clin Pharmaco1,2004 ,z14:520 - 531.
  • 9巴楠,吴敏,王利娟,张红巧.帕洛诺司琼预防高致吐性化疗所致恶心呕吐临床研究[J].实用医学杂志,2011,27(18):3406-3408. 被引量:15
  • 10TANG J, D ANGELO R, WHITE P F, et al. The efficacy of RS -25259, a long - acting selective 5 - HT3 receptor antagonist, for preventing postoperative nausea and vomiting after hysterectomy procedures [ J ]. Anesth Analg, 1998,87:462 - 467.

二级参考文献11

  • 1张晓静,张频.肿瘤化疗所致恶心呕吐的发生机制和药物治疗的研究进展[J].癌症进展,2006,4(4):348-354. 被引量:126
  • 2陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量:48
  • 3Aapro M S, Grunberg S M, Manikhas G M, et al. A phase Ⅲ, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenie chemotherapy [J]. Ann Oncol, 2006,17(9) : 1441-1449.
  • 4Jordan K, Kasper C, Schmoll H J. Chemotherapy-induced and vomiting:Current and new standards in the antiemetic prophylaxis and treatment [J]. Eur J Cancer,2005, 41 (2) : 199-205.
  • 5Geling O, Eichler H G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis systematic re-evaluation of clinical evidence and drug cost implications [J]. J Clin Oncol,2005,23 (6) : 1289-1294.
  • 6Aapro M S. Palonosetron as an anti-emetic and anti-nausea agent in oncology [J]. Ther Clin Risk Manag,2007,3(6): 1009-1020.
  • 7Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during ehemotherapy:a double-hlind,double-dummy,randomised,comparative phase Ⅲ trial [ J ]. Lancet Oncol, 2009, 10 ( 2 ) : 115-124.
  • 8Hunt T L, Gallagher S C, Cullen Jr M T, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [J ]. J Clin Pharmacol, 2005, 45(5) :589-596.
  • 9潘宏铭,徐农.肿瘤内科疾病临床治疗与合理用药[M].北京:科学技术文献出版社,2007.574-585.
  • 10王朝阳,李桂生.格拉司琼联合地塞米松、胃复安及小剂量舒乐安定防治顺铂所致呕吐的疗效观察[J].实用医学杂志,2008,24(3):455-457. 被引量:8

共引文献14

同被引文献61

  • 1宫颈癌及癌前病变规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(8):40-49. 被引量:225
  • 2Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol, 2007,61 ( 2 ) : 162 -175.
  • 3Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med ,2008,358 (23) :2482-2494.
  • 4Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol,2005,3 (5) :369-374.
  • 5Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogeniccisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol,2004,15 (2) :330-337.
  • 6Aapro MS, Gnmt~rg SM,Manikhas GM,et al. A phase Ⅲ, doubleblind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Onco1,2006 ,17 (9) : 1441-1449.
  • 7Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting:a meta-analysis of randomized evidence. J Clin Oncol,2000,18(19):3409-3422.
  • 8Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemeticprophylaxis and treatment. Eur J Cancer,2005,41 (2) :199-205.
  • 9Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol,2007,18 (2) :233-240.
  • 10Aapro M,Fabi A,Nole F,et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plusdexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention ofnausea and vomiting induced by moderately emetogenic chemotherapy. Ann Onco1,2010,21(5) : 11383-1088.

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部